Gastrocrom (Oral)

Quick links

Choose a section

Quick links to important sections

Advertisements

Gastrocrom (Oral)

Selected form

Advertisements
Advertisements

Overview of Gastrocrom (Oral)

What is Gastrocrom (Oral)?

Gastrocrom is a brand-name prescription medication containing the active ingredient cromolyn sodium. It belongs to a class of drugs known as mast cell stabilizers. Unlike medications that treat symptoms after they occur, Gastrocrom works by preventing certain cells in the body from releasing substances that cause inflammation and allergic reactions.

Therapeutic Purpose

This oral solution is specifically designed to manage a rare condition called mastocytosis. Mastocytosis occurs when the body produces too many mast cells, which are a type of white blood cell involved in the immune system. When these cells are overactive or too numerous, they release chemicals like histamine that can cause various systemic symptoms.

How It Works

Gastrocrom works at the cellular level to provide stability to the membrane of mast cells. By doing so, it inhibits the degranulation process—the release of inflammatory mediators. This helps to alleviate symptoms associated with mastocytosis, which may include:

  • Skin reactions (itching or flushing)
  • Gastrointestinal issues (diarrhea or abdominal pain)
  • Headaches

Because the medication is poorly absorbed into the bloodstream from the gastrointestinal tract, much of its action is localized within the digestive system, though it provides systemic relief for patients with mast cell disorders.

Advertisements

What side effects are possible with Gastrocrom (Oral)?

Possible Side Effects and Safety Information

The official safety profile for Sodium Cromoglycate Oral Solution (Gastrocrom) classifies possible adverse reactions primarily based on the system or organ class affected and their frequency of occurrence, as defined by government regulatory documents.

Adverse Reaction Classification

The majority of reported adverse reactions are grouped within Gastrointestinal Disorders, reflecting the medicine's localized, non-systemic action. Effects such as diarrhea, abdominal pain, nausea, flatulence, and headache are classified as common in the regulatory documents. Infrequent reactions can include constipation, vomiting, and tiredness. Certain gastrointestinal effects may be more commonly observed and often transient at the start of therapy.

System-Organ Class Examples of Documented Reactions
Gastrointestinal Disorders Diarrhea, Abdominal pain, Nausea, Vomiting, Flatulence, Constipation
Nervous System Disorders Headache, Lightheadedness
Skin and Subcutaneous Tissue Disorders Rash, Pruritus

Serious Safety Considerations

The regulatory label documents the potential for serious hypersensitivity reactions, including anaphylaxis and angioedema (swelling of the face, tongue, and throat). The medicine is contraindicated for individuals with a known hypersensitivity to Sodium Cromoglycate or any component of the formulation.

Population-Specific Notes

The official label includes specific safety notes for certain patient populations. It is classified as Pregnancy Category B. Safety and effectiveness have been established for use in pediatric patients 2 years of age and older. No significant differences in the safety profile have been identified in geriatric patients.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile of Gastrocrom (Oral) Solution (Cromolyn Sodium) is characterized by an extremely low order of inherent toxicity. Regulatory documents confirm that there is no recognized clinical syndrome associated with an overdosage of cromolyn sodium. Toxicity has only been demonstrated in controlled acute testing at very high exposure levels, regardless of the route of administration.

Regulators emphasize that management following a suspected overdosage is primarily focused on medical observation and the provision of symptomatic treatment. The drug's limited systemic absorption profile supports the regulatory guidance that no action other than medical observation should be necessary. No specific antidote for cromolyn sodium overdose is documented in the official regulatory labeling.


Regulatory-Mandated Emergency Actions

Situation Required Action (as Labeled)
Suspected Overdose Seek immediate medical attention and contact a poison control center or emergency room at once.
Management Symptomatic treatment and medical observation are the procedural actions described in regulatory summaries.
Specific Manifestations No specific clinical syndrome is associated with overdosage.

Urgent medical help must be sought promptly upon any suspected overdosage, according to government-authorized patient information. The regulatory guidance for this medication does not include specific overdose management considerations tied to pediatric or other patient populations.

Advertisements

Therapeutic Uses of Gastrocrom (Oral)

What Gastrocrom (Oral) treats: main uses and benefits

Gastrocrom (Oral) is commonly used in therapeutic domains involving certain distressing symptoms and may be part of symptomatic management applied across domains where additional symptomatic support is needed. It is considered relevant in conditions such as mastocytosis. The use of this medication is considered relevant for easing symptoms that interfere with daily functioning.

The medication is relevant for managing symptoms related to systemic imbalance and chronic digestive distress. It is commonly used to help manage symptom clusters that may become intense or disruptive, such as those related to diarrhea, abdominal cramping, nausea, vomiting, headaches, and flushing. It is considered relevant in conditions where symptoms may intensify temporarily in adults and children.

“This supportive therapeutic benefit may help reduce the symptomatic load and may assist with maintaining functional stability when symptoms interfere with routine activities.”

It is applied in scenarios where additional management of discomfort is required due to symptom clusters that affect the digestive system or present as systemic episodes. This provides support that helps ease the overall symptom burden and may contribute to easing the overall symptom load during periods of heightened symptoms.

Quick Fact: Support for Chronic Diarrhea Gastrocrom is commonly used to help manage the persistent diarrhea that is often associated with the underlying condition, which may support general well-being during symptomatic phases.

Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Gastrocrom (Oral)?

The eligibility for using Gastrocrom (Cromolyn Sodium Oral Solution) is strictly defined by regulatory documents based on patient populations and specific health conditions. The medicine is contraindicated in any patient with a known hypersensitivity or allergy to cromolyn sodium or its excipients.


Age and Organ Function Eligibility

Population Group Regulatory Status / Limitation
Adults and Children (2 years and older) Approved for use
Children (Under 2 years of age) Safety and efficacy not established; reserved for severe disease
Older Adults (Geriatric) Use requires caution; dosage should start at the low end
Decreased Renal/Hepatic Function Use requires caution; a decrease in recommended dosage is necessary

Special Populations

Use during pregnancy is assigned Category B and is permitted only if clearly needed. For nursing mothers, caution should be exercised as it is unknown if the active ingredient is excreted in human milk. Additionally, the regulatory label advises caution for patients with a history of cardiac arrhythmia, defining a condition-specific restriction.

Advertisements

What should I know about interactions with other medicines?

Official Regulatory Interaction Profile

The official regulatory profile for Gastrocrom (Oral) is defined by the drug's unique pharmacokinetic properties, specifically its minimal systemic absorption—typically less than two percent of the dose—and its lack of hepatic metabolism. This non-systemic characteristic results in a low risk for traditional systemic drug-drug interactions (DDI).

Systemic Drug-Drug Interaction Status

The active ingredient, Cromolyn Sodium, is not metabolized by the liver; this feature officially precludes pharmacokinetic interactions involving the CYP450 enzyme system. Consequently, major regulatory labeling does not list any specific medicinal products as formally contraindicated for co-administration due to systemic interaction risks.

Product and Timing Restrictions

Administration is subject to mandatory timing rules essential for the drug’s intended local action. The oral solution must be taken at least 30 minutes before meals and at bedtime, as stated in the prescribing information. Furthermore, official restrictions note that the solution should not be mixed with products such as fruit juice or milk, as this may interfere with its efficacy.

Population-Specific Clearance Considerations

Official caution is documented regarding the risk of altered exposure in specific populations. Since the drug is excreted via the biliary and renal routes, patients with decreased hepatic or renal function may be at risk of increased systemic effects due to impaired clearance. To manage this officially noted risk, the recommended dosage should be decreased in these patient populations.

Advertisements

Mechanism of Action

How Gastrocrom (Oral) Works

Gastrocrom (Cromolyn Sodium) is classified as a targeted modulator whose action is primarily localized to the gastrointestinal mucosa. Its core function is to act as a mast cell stabilizer, engaging with the mast cell membrane to modulate cellular activity.

Cellular Stabilization and Prevention of Mediator Release

This mechanism involves influencing the movement of calcium ions ( Ca^2+) across the mast cell membrane. By modulating this Ca^2+ influx, the drug interrupts the critical intracellular signaling cascade required for degranulation (exocytosis). This intervention prevents the release of pre-formed inflammatory chemicals, including histamine and leukotrienes, from the mast cell into the surrounding tissue, limiting the magnitude of localized immune cell activation.

Modulation of Localized Inflammatory Cascades

The inhibition of mediator release directly influences subsequent inflammatory cascades. By reducing the concentration of potent chemical signals in the tissue, the drug reduces the intensity of localized signaling that follows mast cell activation. This mechanism contributes to the stabilization of the mucosal barrier properties, leading to the modulation of physiological responses at the gut surface.

Advertisements

Dosage and Administration Information

How to Use Gastrocrom (Oral)

Gastrocrom is a prescription Oral Solution containing Cromolyn Sodium that is intended for the oral route of administration only; it is explicitly not intended for inhalation or injection. The administration protocol is based on a structured, fixed daily schedule and requires specific preparation steps to ensure proper use.


Official Dosing and Administration Protocol

The medicine is administered four times daily (QID) at regular intervals throughout the day. The standardized timing requires doses to be taken one-half hour before meals (breakfast, lunch, and dinner) and again at bedtime.

Patient Population Initial Labeled Dose (per dose, QID)
Adults and Adolescents (13+ years) 200 mg (two 5 mL ampules)
Children (2–12 years) 100 mg (one 5 mL ampule)

Preparation and Long-Term Use

For proper intake, the contents of the ampule(s) must be mixed completely into a glass of water immediately prior to consumption, and the entire prepared solution must be fully consumed. The therapy is designed for long-term maintenance and a consistent routine is essential for its proper application.

Once symptomatic control is established, the long-term goal is to reduce the dose to the minimum amount necessary to sustain control. Dosage adjustments are officially required for patients with reduced renal or hepatic function, where the oral dose should be decreased to account for altered elimination.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Gastrocrom (Oral)

Evidence from Studies for Mastocytosis

Oral cromolyn sodium was evaluated in studies involving patients with systemic and cutaneous mastocytosis. Research has explored patterns related to symptom changes in studies conducted during periods of increased symptom activity. These studies included Randomized Controlled Trials (RCTs), where the medicine was observed against either an inactive substance (placebo) or an active comparator. The research includes placebo-controlled crossover designs and studies involving an active comparator. This approach was used in research exploring how symptoms change over defined time intervals.

Studies examined outcomes related to physical discomfort experienced by patients. Findings describe patterns observed in the studies related to symptoms such as diarrhea, abdominal pain, and nausea. Research also examined outcomes related to cutaneous manifestations—skin-related problems like flushing and itching—that can be associated with the condition. Across the trials, data show patterns related to symptom score changes, and physician evaluations also reported on changes in overall disease status measured during the study period.

Focus of Research: Symptoms and Overall Disease Status

The primary focus of the trials was to assess outcomes describing perceived discomfort in the observed populations with mastocytosis. Studies monitored patient-reported outcomes using symptom diaries and standardized scales. Research examined outcomes capturing phases of heightened symptom activity, which included assessing whether reported symptom intensity or frequency changed during the study periods. The studies report how symptoms evolved and contributed to understanding the observed symptom patterns in the specific populations evaluated.

Follow-up and Observation Periods in Clinical Trials

The evidence derived from the core clinical program is primarily short-term. The main controlled trials had observation periods of up to 16 weeks. Research explored short-term symptom changes, with studies monitoring responses over these defined time intervals. Changes in symptom scores were reported within the first 2 to 6 weeks of starting the study protocol. This initial phase of change was studied, and the research provides context regarding symptom patterns during these limited follow-up durations.

Studies in Specific Patient Groups

Oral cromolyn sodium was evaluated in the specific patient population diagnosed with mastocytosis, which encompassed both adults and pediatric patients (starting from two years of age). These studies were relevant in trials assessing short-term or episodic symptom patterns experienced by both groups. The results apply only to the populations studied and do not provide information regarding use outside of this specific, rare patient group. Data for certain groups, such as older adults or those with other significant comorbidities, remain insufficient because the studies were narrowly focused.

Understanding the Strength and Limitations of the Evidence

The evidence base, which includes controlled designs, has certain structural limitations. The initial clinical program for this medicine was conducted on a very small number of evaluable patients due to the rarity of mastocytosis. Furthermore, the limited information suggests that formal statistical analyses were not performed on the primary outcomes in some of the initial registration trials. The evidence contributes to the broader evidence landscape.

Areas of Research Uncertainty and Gaps

There are several areas where research remains insufficient. Long-term effects are not fully established, as the follow-up durations were limited to a few months in the core studies. Data for long-term outcomes and maintenance therapy over many years remain insufficient. Because the research was specific to systemic and cutaneous mastocytosis, evidence quality varies across studies, and comparative evidence for other conditions is lacking. Additionally, research for certain aspects of the condition is ongoing, and findings were not uniform across all small studies.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Gastrocrom (Oral) (FAQ)


Q: Is Gastrocrom used for general allergies or only food-related issues?

A: Official regulatory documentation indicates that the oral form of this medicine is approved for the management of mastocytosis. The official prescribing label does not include generalized allergic reactions as an indicated use for this specific oral formulation.


Q: Does Gastrocrom interact with common pain relievers like ibuprofen?

A: The active ingredient in Gastrocrom is minimally absorbed into the bloodstream and is not processed by the liver's enzyme system. This unique profile, described in official documents, is consistent with a reduced potential for systemic drug-drug interactions with other medicinal products, including many common pain relievers.


Q: Are there any known issues combining Gastrocrom with over-the-counter allergy medications?

A: Regulatory documents do not list specific over-the-counter allergy medications as having known or contraindicated interactions with Gastrocrom. This aligns with the medicine's non-systemic nature, as minimal amounts of the drug are absorbed into the body.


Q: Does taking Gastrocrom affect liver function?

A: Official documentation notes that patients who already have decreased liver (hepatic) function may require a dose adjustment. This is because impaired liver clearance could affect how the medicine is processed. The label requires this precaution, but it does not state that the drug causes liver function changes in people with healthy liver function.


Q: Can Gastrocrom make you feel tired or drowsy?

A: Reported infrequent adverse reactions in regulatory documents include general feelings of discomfort (Malaise) and Tiredness. Drowsiness is not consistently listed as a common or frequent side effect in the official safety profile.


Q: What happens if I miss a dose of Gastrocrom?

A: Official instructions indicate that a missed dose may be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, in which case the missed dose is instructed to be skipped. Official instructions caution against taking extra medicine to make up for a dose that was missed.


Q: Does Gastrocrom have any known food interactions?

A: Official instructions specify that the oral solution must not be mixed with fruit juice or milk, as this may interfere with its efficacy. Furthermore, the medicine is required to be taken on a precise schedule, which involves taking it 30 minutes before meals.


Q: Is it safe to drink alcohol while taking Gastrocrom?

A: The official product labeling does not contain a specific contraindication or warning against alcohol consumption. However, the official label advises that patients are expected to discuss the use of alcohol with their healthcare professional while using any prescription medicine.


Q: Has Gastrocrom been studied in elderly patients?

A: Clinical studies did not include sufficient elderly patients (aged 65 and over) to formally determine if they respond differently than younger adults. Regulatory notes indicate that no overall differences in the safety profile have been identified in the elderly since the product became available.


Q: What is the regulatory status of Gastrocrom in different countries?

A: The regulatory status of the active ingredient, Cromolyn Sodium, varies globally. The oral solution is generally categorized as prescription-only (Rx) in major regions. However, other formulations of the drug, such as nasal or eye drops, may be available over-the-counter (OTC) in certain countries.


Q: Are there any known interactions between Gastrocrom and herbal supplements?

A: The official documentation provides a general caution that patients should inform their healthcare providers about all medicines and products they use. This includes all herbal products and dietary supplements, though specific known interactions are not listed.

Advertisements

How should Gastrocrom (Oral) be stored and disposed of?

Official Storage and Disposal Requirements

The storage of Gastrocrom (Cromolyn Sodium Oral Solution) is strictly governed by regulatory requirements to ensure product stability.

Item Requirement
Storage Temperature Store between mathbf20^circC and mathbf25^circC (mathbf68^circF and mathbf77^circF), which is Controlled Room Temperature.
Protection Rules The solution must be mathbfprotected from light and ampules must be mathbfretained in their original foil pouch until ready for use.
Integrity Check mathbfDo not use the solution if it contains a precipitate (particles/cloudiness) or becomes discolored.
Child Safety This and all medications must be mathbfkept out of the reach of children.
Disposal Instructions Unused or expired medication must be disposed of according to local regulations or official governmental take-back programs.

These mandated conditions define how the product must be protected from environmental factors like heat and light. Following these rules, including retaining the product in the foil pouch, is necessary to maintain stability. Disposal must adhere to specific local guidance for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Gastrocrom (Oral) found in:

A-Z Index: